Positives

• Patients using PE-22-28 describe rapid mood improvement, with some reporting effects within days rather than the weeks needed for conventional antidepressants.
  
  
• One patient reported clearer short-term memory and steadier focus alongside the mood lift.
  
  

Negatives

• Patients note that experiential reports outpace controlled human evidence, and individual response is highly variable.
  
  
• A patient reported only modest benefit and questioned whether expectation accounted for some of the perceived effect.
  
  

Hurdles & Side Effects

• PE-22-28 is preclinical, not FDA-approved, and has no validated dosing protocol for humans.
  
  
• Sourcing is grey-market and patients describe difficulty finding any clinician willing to supervise its use.